Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study
SGLT2i therapy was associated with reduced risk of all-cause mortality and HF-related hospitalizations following pacemaker implantation. Future randomized studies are needed to confirm this association.
Authors
- Amir Yahav (ORCID: https://orcid.org/0000-0002-8686-2431)
- Yuval Avidan (ORCID: https://orcid.org/0000-0002-8440-8892)
- Amir Aker (ORCID: https://orcid.org/0000-0002-3724-6691)
- Asaf Danon (ORCID: https://orcid.org/0000-0001-9250-596X)
- Oren Caspi (ORCID: https://orcid.org/0000-0002-2464-7357)
- Sameer Kassem (ORCID: https://orcid.org/0000-0003-3588-0338)
- Dana Hadar
Institutions
- Rambam Health Care Campus (IL)
- Carmel Medical Center (IL)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s12933-025-02992-2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00